Michael Cross

Head of Laboratory Research

Leipzig University

Germany

Research Interests

Explore related searches

Professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Michael Cross is the Head of Laboratory Research at the University of Leipzig, Germany. His research focuses on hematology, particularly in the areas of acute myeloid leukemia (AML), clonal hematopoiesis, and stem cell transplantation. Recent publications highlight significant findings related to microRNA's role in leukemia, chemotherapy resistance, and the impact of graft-versus-host disease in transplantation scenarios.

Articles (10)

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (3)

Petra Büttner

Head of Lab

Heart Center Leipzig at University of Leipzig

GERMANY

View details

Klaus Metzeler

Professor of Translational Hematology

Leipzig University

GERMANY

View details

haifa kathrin al-ali

University Hospital Halle (Saale)

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michael Cross

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

MicroRNA Screening Reveals Upregulation of FoxO-Signaling in Relapsed Acute Myeloid Leukemia Patients

Clonal Hematopoiesis Mutations Are Present in Atherosclerotic Lesions in Peripheral Artery Disease

MicroRNA Expression Patterns Reveal a Role of the TGF-β Family Signaling in AML Chemo-Resistance

How Azanucleosides Affect Myeloid Cell Fate

Correction to: Allogeneic hematopoietic stem cell transplantation improves long‑term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.

Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.

Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells

Reduction of Graft-versus-Host-Disease in NOD.Cg-Prkdc<sup>scid</sup> Il2rg<sup>tm1Wjl</sup>/SzJ (NSG) Mice by Cotransplantation of Syngeneic Human Umbilical Cord-Derived Mesenchymal Stromal Cells: M. Hansen et al

Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells—Report on Two Cases

Stem-cell mobilization of healthy sibling donors with pegfilgrastim—A prospective open-label phase II trial (EudraCT no: 2005-004971-39)

Collaborators (3)

Petra Büttner

Klaus Metzeler

haifa kathrin al-ali

Make your next move.